Older adults with gastric cancer achieve comparable survival despite higher toxicity and treatment modifications
Older adults with gastric cancer show similar survival to younger patients
This secondary analysis of a Phase III trial involved 574 patients with resectable gastric or gastro-esophageal junction adenocarcinoma. Old…
Older adults with gastric cancer can achieve similar survival rates to younger patients, even though they may face more treatment side effec…
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…